Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$6.94
<$0.01(0.02%)
At close: 4:00 PM EST
$6.94
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$4.50 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)87.53K
Market Cap
$134.78M
Enterprise Value$41.89M
Total Cash (Recent Filing)$54.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 26, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding21,774,103
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$15.00Price Target Upside116.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$23.60M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet And Cash On HandA debt-free balance sheet and $54.2M in cash provide durable financial flexibility to fund near-term commercialization and clinical milestones without immediate refinancing. This reduces solvency risk and supports planned investment in sales, evidence generation, and regulatory tasks over coming quarters.
Rapid Revenue Scaling With High Repeat UsageStrong sequential revenue growth and high repeat prescribing indicate accelerating product adoption and consumer/provider acceptance, signaling product-market fit. Combined with high gross margins, this trend supports scalable revenue expansion and the potential to absorb fixed commercial costs over the medium term.
Commercial Buildout, Payer Contracts, And IP ProtectionA staffed commercial organization, existing PBM contracts covering tens of millions of lives, and issued patents through 2045 form durable competitive advantages. Together they support distribution scale, payer engagement, and long-term exclusivity that can protect revenue as adoption and evidence accumulate.
Bears Say
Significant Cash Burn And Declining Cash BalanceSustained negative operating cash flow and a meaningful quarter-over-quarter cash decline highlight dependence on external funding unless revenue scales or spending is cut. With quarterly operating spend near $12M, runway is finite and financing risk or dilution remains a persistent structural concern.
Deep And Persistent UnprofitabilityVery negative margins reflect that commercial and R&D costs far outpace current revenue. Achieving operating leverage requires sustained revenue growth; until scale is achieved, profitability targets remain aspirational and the company will likely continue to consume capital over multiple quarters.
Limited Downstream Payer Implementation And Reliance On Data CatalystsLow downstream PBM implementation constrains realized patient access despite contractual coverage, and commercial expansion is tightly linked to upcoming clinical and real-world data. Delays or unfavorable results could materially slow formulary uptake, prescribing growth, and revenue durability.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $134.78M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Aug 26, 2026 which is in 86 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on May 14, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.387 by $0.067.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.41.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,774,103 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.387. Following the earnings report the stock price went up 5.986%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (116.14% Upside)
$15.00 (116.14% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
-54.13%
Trailing 12-Months
Asset Growth
42.46%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong early commercial trajectory for ZUNVEYL with clear sequential growth in revenue (40% QoQ), accelerating prescription metrics (bottles +23% QoQ, prescriber calls +93% QoQ) and multiple near-term clinical and IP catalysts (BEACON, CONVERGE, sublingual PK, two patents to 2045). Management is deliberately investing in a 60-person commercial team, payer engagement, and real-world evidence generation to drive broader access and expects operating profitability in 2027. Offsetting these positives are meaningful near-term challenges: increased net losses and operating spend, cash decline, limited downstream PBM implementation (~16% of book), and reliance on upcoming data to expand payer coverage. Overall the call was upbeat and progressing toward commercialization scale, but the company remains in an investment phase with execution and payer adoption as key near-term risks.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$15.00
▲(116.14% Upside)
Technical Analysis
Sangamo Therapeutics
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
18.08% Insiders
0.06% Mutual Funds
46.29% Other Institutional Investors
35.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---